MARKET

FCSC

FCSC

Fibrocel Science
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.990
0.000
0.00%
Closed 16:00 12/06 EST
OPEN
2.990
PREV CLOSE
2.990
HIGH
3.000
LOW
2.990
VOLUME
23.39K
TURNOVER
--
52 WEEK HIGH
3.280
52 WEEK LOW
1.450
MARKET CAP
29.18M
P/E (TTM)
-8.0247
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of FCSC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

FCSC News

  • Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders FCSC, PRTO, ARTX, ROAN
  • GlobeNewswire.11/01 19:40
  • SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Fibrocell Science, Inc. (NASDAQ GS: FCSC)
  • ACCESSWIRE.10/28 22:36
  • SHAREHOLDER ALERT: WeissLaw LLP Investigates Fibrocell Science, Inc.
  • PR Newswire.10/25 23:00
  • Merger Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders ROAN, UCFC, SRCI, FCSC
  • GlobeNewswire.10/22 20:09

More

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.32%

Hot Stocks

Name
Price
%Change

About FCSC

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
More

Webull offers Fibrocell Science Inc (FCSC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.